Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Haematologica Année : 2015

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

Leonard Minuk
  • Fonction : Auteur
Jean-Claude Eisenmann
  • Fonction : Auteur
Serge Leyvraz
  • Fonction : Auteur
Christian Langer
  • Fonction : Auteur
Yousef Ezaydi
  • Fonction : Auteur
Dan T. Vogl
  • Fonction : Auteur
Pilar Giraldo-Castellano
  • Fonction : Auteur
Sung-Soo Yoon
  • Fonction : Auteur
Bernard Lemieux
  • Fonction : Auteur
Kevin Song
  • Fonction : Auteur
Nizar Jacques Bahlis
  • Fonction : Auteur
Shien Guo
  • Fonction : Auteur
Mara Silva Monzini
  • Fonction : Auteur
Annette Ervin-Haynes
  • Fonction : Auteur
Vanessa Houck
  • Fonction : Auteur
Michel Delforge
  • Fonction : Auteur
  • PersonId : 907571

Résumé

We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexamethasone, and melphalan, prednisone, thalidomide improved patients' health-related quality-of-life from baseline over the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalidomide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeated-measures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and low-dose dexamethasone delays disease progression versus melphalan, prednisone, thalidomide and has been associated with a clinically meaningful improvement in health-related quality-of-life. These results further establish continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone, thalidomide

Dates et versions

hal-01274909 , version 1 (16-02-2016)

Identifiants

Citer

Leonard Minuk, Jean-Claude Eisenmann, Bertrand Arnulf, Letizia Canepa, Alberto Fragasso, et al.. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica, 2015, 100 (6), pp.826--833. ⟨10.3324/haematol.2014.120121⟩. ⟨hal-01274909⟩
36 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More